Sphingosine kinase 1/sphingosine 1-phosphate signalling pathway as a potential therapeutic target of pulmonary hypertension

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 8, 2015, Pages 11930-11935

  Xing, Xi Qian ^a   Li, Yan Li ^a   Zhang, Yu Xuan ^a   Xiao, Yi ^a   Li, Zhi Dong ^a   Liu, Li Qiong ^a   Zhou, Yu Shan ^a   Zhang, Hong Yan ^a   Liu, Yan Hong ^a   Zhang, Li Hui ^a   Zhuang, Min ^a   Chen, Yan Ping ^a   Ouyang, Sheng Rong ^a   Wu, Xu Wei ^a   Yang, Jiao ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Endothelial dysfunction; Pulmonary hypertension; Pulmonary vascular remodeling; Sphingosine 1 phosphate; Vascular smooth muscle cell

Indexed keywords

ANTIHYPERTENSIVE AGENT; DEXTRO ERYTHRO N,N DIMETHYL SPHINGOSINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTACYCLIN; RHO KINASE; SKI 2; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE INHIBITOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 1 INHIBITOR; UNCLASSIFIED DRUG;

BLOOD VESSEL TONE; CELL MIGRATION; CELL PROLIFERATION; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPOXIA-INDUCED PULMONARY HYPERTENSION; MYOFIBROBLAST; NONHUMAN; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR REMODELING; VASOCONSTRICTION; VASODILATATION;

EID: 84943328757     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Zaiman A, Fijalkowska I, Hassoun PM and Tuder RM. One hundred years of research in the pathogenesis of pulmonary hypertension. Am J Respir Cell Mol Biol 2005; 33: 425-431.
2. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Moliterno DJ, Mukherjee D, Pohost GM, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH and Wesley DJ. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250-2294.
3. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF and Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 13S-24S.
4. Dantas AP, Igarashi J and Michel T. Sphingo-sine 1-phosphate and control of vascular tone. Am J Physiol Heart Circ Physiol 2003; 284: H2045-2052.
5. Tao R, Zhang J, Vessey DA, Honbo N and Karliner JS. Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res 2007; 74: 56-63.
6. Maceyka M, Payne SG, Milstien S and Spiegel S. Sphingosine kinase, sphingosine-1-phosphate,and apoptosis. Biochim Biophys Acta 2002; 1585: 193-201.
7. Saba JD and Hla T. Point-counterpoint of sphingosine 1-phosphate metabolism. Circ Res 2004; 94: 724-734.
8. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng YW, Huang Y, Cyster JG and Coughlin SR. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007; 316: 295-298.
9. Salomone S, Yoshimura S, Reuter U, Foley M, Thomas SS, Moskowitz MA and Waeber C. S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. Eur J Pharmacol 2003; 469: 125-134.
10. Coussin F, Scott RH, Wise A and Nixon GF. Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ Res 2002; 91: 151-157.
11. Wamhoff BR, Lynch KR, Macdonald TL and Owens GK. Sphingosine-1-phosphate receptor subtypes differentially regulate smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 2008; 28: 1454-1461.
12. Inoue S, Nakazawa T, Cho A, Dastvan F, Shilling D, Daum G and Reidy M. Regulation of arterial lesions in mice depends on differential smooth muscle cell migration: a role for sphingosine-1-phosphate receptors. J Vasc Surg 2007; 46: 756-763.
13. Spiegel S and Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003; 4: 397-407.
14. Ogretmen B and Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4: 604-616.
15. Tani M, Sano T, Ito M and Igarashi Y. Mechanisms of sphingosine and sphingosine 1-phosphate generation in human platelets. J Lipid Res 2005; 46: 2458-2467.
16. Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL, Parikh NS, Habrukowich C and Hla T. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res 2008; 102: 669-676.
17. Murata N, Sato K, Kon J, Tomura H and Okajima F. Quantitative measurement of sphingosine 1-phosphate by radioreceptor-binding assay. Anal Biochem 2000; 282: 115-120.
18. Hla T, Lee MJ, Ancellin N, Paik JH and Kluk MJ. Lysophospholipids--receptor revelations. Science 2001; 294: 1875-1878.
19. Usui S, Sugimoto N, Takuwa N, Sakagami S, Takata S, Kaneko S and Takuwa Y. Blood lipid mediator sphingosine 1-phosphate potently stimulates platelet-derived growth factor-A and -B chain expression through S1P1-Gi-Ras-MAPK-dependent induction of Kruppel-like factor 5. J Biol Chem 2004; 279: 12300-12311.
20. Kono M, Mi Y, Liu Y, Sasaki T, Allende ML, Wu YP, Yamashita T and Proia RL. The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J Biol Chem 2004; 279: 29367-29373.
21. Harvey KA, Welch Z, Sliva D and Siddiqui RA. Role of Rho kinase in sphingosine 1-phosphate-mediated endothelial and smooth muscle cell migration and differentiation. Mol Cell Biochem 2010; 342: 7-19.
22. Cella G, Bellotto F, Tona F, Sbarai A, Mazzaro G, Motta G and Fareed J. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 2001; 120: 1226-1230.
23. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D and Voelkel NF. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-1932.
24. Frasch HF, Marshall C and Marshall BE. Endothelin-1 is elevated in monocrotaline pulmonary hypertension. Am J Physiol 1999; 276: L304-310.
25. Machida T, Hamaya Y, Izumi S, Iizuka K, Igarashi Y, Minami M, Levi R and Hirafuji M. Sphingosine 1-phosphate inhibits nitric oxide production induced by interleukin-1beta in rat vascular smooth muscle cells. J Pharmacol Exp Ther 2008; 325: 200-209.
26. Morales-Ruiz M, Lee MJ, Zollner S, Gratton JP, Scotland R, Shiojima I, Walsh K, Hla T and Sessa WC. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem 2001; 276: 19672-19677.
27. Kimura T, Sato K, Kuwabara A, Tomura H, Ishiwara M, Kobayashi I, Ui M and Okajima F. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 2001; 276: 31780-31785.
28. Damirin A, Tomura H, Komachi M, Tobo M, Sato K, Mogi C, Nochi H, Tamoto K and Okajima F. Sphingosine 1-phosphate receptors mediate the lipid-induced cAMP accumulation through cyclooxygenase-2/prostaglandin I2 pathway in human coronary artery smooth muscle cells. Mol Pharmacol 2005; 67: 1177-1185.
29. Nodai A, Machida T, Izumi S, Hamaya Y, Kohno T, Igarashi Y, Iizuka K, Minami M and Hirafuji M. Sphingosine 1-phosphate induces cyclo-oxygenase-2 via Ca2+-dependent, but MAPK-independent mechanism in rat vascular smooth muscle cells. Life Sci 2007; 80: 1768-1776.
30. Hsiao SH, Constable PD, Smith GW and Haschek WM. Effects of exogenous sphinganine, sphingosine, and sphingosine-1-phosphate on relaxation and contraction of porcine thoracic aortic and pulmonary arterial rings. Toxicol Sci 2005; 86: 194-199.
31. Thomas GD, Snetkov VA, Patel R, Leach RM, Aaronson PI and Ward JP. Sphingosylpho-sphorylcholine-induced vasoconstriction of pulmonary artery: activation of non-store-operated Ca2+ entry. Cardiovasc Res 2005; 68: 56-64.
32. Szczepaniak WS, Pitt BR and McVerry BJ. S1P2 receptor-dependent Rho-kinase activation mediates vasoconstriction in the murine pulmonary circulation induced by sphingosine 1-phosphate. Am J Physiol Lung Cell Mol Physiol 2010; 299: L137-145.
33. Ota H, Beutz MA, Ito M, Abe K, Oka M and McMurtry IF. S1P(4) receptor mediates S1P-induced vasoconstriction in normotensive and hypertensive rat lungs. Pulm Circ 2011; 1: 399-404.
34. Chan SY and Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol 2008; 44: 14-30.
35. Stenmark KR, Fagan KA and Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006; 99: 675-691.
36. Jeffery TK and Wanstall JC. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 2001; 92: 1-20.
37. Tanski W, Roztocil E and Davies MG. Sphingosine-1-phosphate induces G(alphai)-coupled, PI3K/ras-dependent smooth muscle cell migration. J Surg Res 2002; 108: 98-106.
38. Yun JK and Kester M. Regulatory role of sphingomyelin metabolites in hypoxia-induced vascular smooth muscle cell proliferation. Arch Biochem Biophys 2002; 408: 78-86.
39. McDonald RA, Pyne S, Pyne NJ, Grant A, Wainwright CL and Wadsworth RM. The sphingosine kinase inhibitor N,N-dimethylsphingo-sine inhibits neointimal hyperplasia. Br J Pharmacol 2010; 159: 543-553.
40. Ahmad M, Long JS, Pyne NJ and Pyne S. The effect of hypoxia on lipid phosphate receptor and sphingosine kinase expression and mitogen-activated protein kinase signaling in human pulmonary smooth muscle cells. Prosta-glandins Other Lipid Mediat 2006; 79: 278-286.
41. Ryu Y, Takuwa N, Sugimoto N, Sakurada S, Usui S, Okamoto H, Matsui O and Takuwa Y. Sphingosine-1-phosphate, a platelet-derived lysophospholipid mediator, negatively regulates cellular Rac activity and cell migration in vascular smooth muscle cells. Circ Res 2002; 90: 325-332.
42. Sugimoto N, Takuwa N, Okamoto H, Sakurada S and Takuwa Y. Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol Cell Biol 2003; 23: 1534-1545.
43. Goparaju SK, Jolly PS, Watterson KR, Bektas M, Alvarez S, Sarkar S, Mel L, Ishii I, Chun J, Milstien S and Spiegel S. The S1P2 receptor negatively regulates platelet-derived growth factor-induced motility and proliferation. Mol Cell Biol 2005; 25: 4237-4249.
44. Windh RT, Lee MJ, Hla T, An S, Barr AJ and Manning DR. Differential coupling of the sphingosine1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the G(i), G(q), and G(12) families of heterotrimeric G proteins. J Biol Chem 1999; 274: 27351-27358.
45. Ishii I, Ye X, Friedman B, Kawamura S, Contos JJ, Kingsbury MA, Yang AH, Zhang G, Brown JH and Chun J. Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3. J Biol Chem 2002; 277: 25152-25159.
46. Watterson KR, Ratz PH and Spiegel S. The role of sphingosine-1-phosphate in smooth muscle contraction. Cell Signal 2005; 17: 289-298.
47. Birker-Robaczewska M, Studer R, Haenig B, Menyhart K, Hofmann S and Nayler O. bFGF induces S1P1 receptor expression and functionality in human pulmonary artery smooth muscle cells. J Cell Biochem 2008; 105: 1139-1145.
48. Xing XQ, Gan Y, Wu SJ, Chen P, Zhou R and Xiang XD. Rho-kinase as a potential therapeutic target for the treatment of pulmonary hypertension. Drug News Perspect 2006; 19: 517-522.
49. Xing XQ, Gan Y, Wu SJ, Chen P, Zhou R and Xiang XD. Statins may ameliorate pulmonary hypertension via RhoA/Rho-kinase signaling pathway. Med Hypotheses 2007; 68: 1108-1113.
50. Haberberger RV, Tabeling C, Runciman S, Gutbier B, Konig P, Andratsch M, Schutte H, Suttorp N, Gibbins I and Witzenrath M. Role of sphingosine kinase 1 in allergen-induced pulmonary vascular remodeling and hyperresponsiveness. J Allergy Clin Immunol 2009; 124: 933-941 e931-939.
51. Tonelli F, Lim KG, Loveridge C, Long J, Pitson SM, Tigyi G, Bittman R, Pyne S and Pyne NJ. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal 2010; 22: 1536-1542.
52. Chen J, Tang H, Sysol JR, Moreno-Vinasco L, Shioura KM, Chen T, Gorshkova I, Wang L, Huang LS, Usatyuk PV, Sammani S, Zhou G, Raj JU, Garcia JG, Berdyshev E, Yuan JX, Natarajan V and Machado RF. The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension. Am J Respir Crit Care Med 2014; 190: 1032-1043.